Reason for request


Moderate clinical added value in first-line treatment of advanced melanoma.

  • OPDIVO has marketing authorisation as monotherapy in the treatment of adults with advanced (unresectable or metastatic) melanoma.
  • In the absence of BRAF mutation, like pembrolizumab (KEYTRUDA), it is recommended as first-line treatment.
  •  If there is BRAF mutation, like pembrolizumab (KEYTRUDA), its role as an alternative to targeted therapies is currently debated, especially the patient profile that could receive one of these two treatments as a first line.


Clinical Benefit



Clinical Added Value



Therapeutic use




Contact Us

Évaluation des médicaments